$3,399.00
In Stock
Indications for the drug Stivarga
– Metastatic colorectal cancer in patients who have already received or are not eligible for fluoropyrimidine chemotherapy, anti-vascular endothelial growth factor (VEGF) therapy, and anti-epidermal growth factor receptor (EGFR) therapy.
– Inoperable or metastatic gastrointestinal stromal tumors in patients who have progressed on therapy with imatinib and sunitinib or who are intolerant to this type of treatment.
– Hepatocellular carcinoma in patients who have already received sorafenib therapy.
Active ingredient: regorafenib
Prescription medicine
